The role of antibody delivery formation in cancer therapy. (2nd July 2020)

• Record Type: Journal Article
• Authors: Qi, Tongtong; Shi, Yanbin; Huang, Yi; Fu, Xianglei; Qiu, Shengnan; Sun, Qifeng; Lin, Guimei
• Is Part Of: Journal of drug targeting. Volume 28:Number 6(2020)
• Page Start: 574
• Page End: 584
• Publication Date: 2020-07-02
• Subjects: Antibody -- antibody-drug conjugate -- liposome -- delivery system -- nanoparticle; Drug delivery systems -- Periodicals; Drug Delivery Systems; Vehicles; Drug Administration Routes; Drug Evaluation; 615.7
• DOI: 10.1080/1061186X.2020.1728537
• Languages: English
• ISSNs: 1061-186X

Abstract

Abstract: Cancer has become one of the major threats to human survival. Because of antibodies specificity and low toxicity, it is the primary choice to diagnose and treat cancer. It is easy to be cleared from the blood circulation or distributing throughout the body and causes unnecessary side effects. It is necessary to delivery antibodies to the tumour region in a stable, safe and effective manner. In this review, we discuss the latest studies that aimed to delivery antibodies to tumour sites via several vector forms, such as liposomes, carbon nanomaterials, and gold nanomaterials. How to deliver antibodies to the target site is a difficulty for antibody therapy. This review summarises the antibody's therapeutic forms and carrier materials in recent years, and to explore how antibodies can be safely and stably delivered to the target site.